



NATIONAL CANCER INSTITUTE, JHAJJAR ALL INDIA INSTITUTE OF MEDICAL SCIENCES

Ansari Nagar, New Delhi-110029 (INDIA)

Dr. Akash Kumar, MD,DM

Associate Professor, Department of Medical Oncology Mob: +91- 9910850134

E-mail: akashjha08@yahoo.com

Office: Room No. 115, 1st Floor,

National Cancer Institute, Badsa, Jhajjar, Campus of All India Institute of Medical Sciences, New Delhi-110029

To: The Sunpharma Clinical research Fellowship Committee,

I recommend Dr. Babita Kataria for the prestigious Sunpharma research fellowship award. I have known Dr. Kataria since September 2015 when she joined our department as a non-academic resident. She has since demonstrated her hard-working nature and dedication to patient care.

Dr. Kataria received her post-graduate degree in General medicine from Delhi University, India in 2015. She was selected as a D.M. resident at AIIMS, Delhi in January 2017. Under the mentorshiDelhi, Professor Dr. Atul Sharma, she conducted a phase II/III Randomised controlled trial (RCT) "Erlotinib or Capecitabine v/s best supportive care alone in unresectable/metastatic gallbladder cancer patients with poor performance status". This study was presented at the Europea. "Society of Medical Oncology World GI Congress 2022 and was one of the five recipients of the "International Developing Nations Travel Award".

Dr. Kataria joined the National Cancer institute (NCI)-AIIMS as an ad-hoc faculty, in April 2020 and was tenured as a full-time faculty in Nov. 2022. She contributed to the departmental protocols under my supervision at NCI-AIIMS.

She recently completed another phase II RCT as Principal Investigator (PI) in supportive care in oncology titled "To test the efficacy of Olanzapine in improving health-related quality of life in cancer patients on palliative chemotherapy". The abstract was selected for oral presentation at the 8th World Cancer Congress 2024,New Delhi India and she received the Dr. Edward Kennedy Memorial Award for the best oral presentation.

Dr. Kataria is focused on gynecological cancers, particularly in finding cost-effective alternatives for common cancers like cervical cancer in low- and middle-income countries

(LMICs). She recently received an intramural grant for her research proposal titled "A multiarm, open-label, phase II randomised, non-comparative trial to test randomizedcy of consolidation chemotherapy in locally advanced cervical cancer (CERCO Trial)."

She has also submitted another research proposal to the Indian Council of Medical Research (ICMR) titled "A Phase II, single-arm prospective trial to test the efficacy of LOw-dose PEmbrolizumab with chemotherapy in persistent, recurrent or metastatic ceRvical cAncer (LOPERA)."

Her trajectory aligns with her goal of finding low-cost solutions for gynaecological cancers in LMICs.

Her research proposal for the Sunpharma Fellowship Award is an extension of the, CERCO trial, which aims to find correlation between post treatment HPVctDNA levels and risk of relapse in locally advanced cervical cancer.

I believe that Dr Kataria is an ideal candidate for the Sunpharma Clinical Research Fellowship Award. This fellowship will ,not only help her project but will also benefit in identifying high risk patients for future treatment escalation trials.

I am optimistic that supporting her research will only further the aim of the Sunpharma Foundation to make can."

We at AII India Institute of Medical Sciences, Delhi and National Cancer Institute-AIIMS, India are dedicated to mentoring Dr. Kat, aria to help her achieve her professional g,,oals and to support the implementation of the expertise she gains from this fellowship.

Thank you for considering Dr. Kataria's application for the fellowship opportunity.

29th October 2024

Badsa, Jhajjar, Haryana